Suppr超能文献

[艾滋病中的贫血:需避免的问题。人重组促红细胞生成素在治疗HIV阳性患者中的应用]

[Anemia in AIDS: the problem to avoid. Human recombinant erythropoietin in the treatment of HIV positive patients].

作者信息

Karwacki M, Ochocka M, Kubiak W

机构信息

Klinika Hematologii i Chorób Rozrostowych Dzieci AM w Warszawie.

出版信息

Przegl Epidemiol. 1994;48(4):441-7.

PMID:7597181
Abstract

The most common hematological abnormality associated with HIV infection is anaemia. The aetiology is multifactorial and may include the HIV virus itself; the anaemia of chronic diseases (ACD); infection with other viruses, mycobacteria and fungi; medications, especially zidovudine; and even B12 deficiency. Erythropoietin insufficiency is present in all anaemic AIDS patients, probably as a result of the mechanism of ACD. The studies, performed in patients with PGL, ARC and AIDS stages of disease demonstrate that rHuEPO is safe, and in dose of 100-200 U/kg b.w. three times a week can alleviate the anemia in AIDS patients taking AZT whose baseline EPO levels are less than 500 mU/ml.

摘要

与HIV感染相关的最常见血液学异常是贫血。病因是多因素的,可能包括HIV病毒本身;慢性病贫血(ACD);感染其他病毒、分枝杆菌和真菌;药物,尤其是齐多夫定;甚至维生素B12缺乏。所有贫血的艾滋病患者均存在促红细胞生成素不足,这可能是ACD机制导致的。在患有PGL、ARC和艾滋病各疾病阶段的患者中进行的研究表明,重组人促红细胞生成素(rHuEPO)是安全的,每周三次、剂量为100 - 200 U/kg体重可缓解基线促红细胞生成素水平低于500 mU/ml且正在服用齐多夫定的艾滋病患者的贫血症状。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验